Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans Marco Colizzi, NathalieWeltens, Philip McGuire, Lukas Van Oudenhove and Sagnik Bhattacharyya Brain Sciences, 2019, 9, 93 doi:10.3390/brainsci9040093 Abstract : Background : Cannabis use can increase the risk of psychosis, and the acute administration of its key psychoactive ingredient, delta-9-tetrahydrocannabinol (D9-THC), can induce transient psychotomimetic symptoms. Methods: A double-blind, randomized, placebo-controlled crossover design was used to investigate the symptomatic eects of acute intravenous administration of D9-THC (1.19 mg/2 mL) in 16 healthy participants (seven males) with modest previous cannabis exposure. Results : In the 20 min following acute D9-THC administration, symptomatic eects of at [...]
Lire la suiteThe effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers C. Hindocha, T. P. Freeman, M. Grabski, H. Crudgington, A. C. Davies, J. B. Stroud, R. K. Das, W. Lawn, C. J. A. Morgan & H. V. Curran Scientific Reports, 2018, 8, 7568 DOI:10.1038/s41598-018-25846-2 Abstract : Acute nicotine abstinence in cigarette smokers results in deficits in performance on specific cognitive processes, including working memory and impulsivity which are important in relapse. Cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, has shown pro-cognitive effects and preliminary evidence has indicated it can reduce the number of cigarettes smoked in dependent smokers. However, the effects [...]
Lire la suiteNew Therapy for Treatment-Resistant Depression Feyza Sancar JAMA, 2019, 321, 15, 1449. doi:10.1001/jama.2019.3596 https://jamanetwork.com/journals/jama/fullarticle/2730598 The FDA has approved esketamine nasal spray as an adjunctive therapy for adults with treatment-resistant depression (TRD), which affects approximately 30% of patients with major depressivedisorder. It’s the first regulatory approval of esketamine, the s-enantiomer of ketamine, for any psychiatric condition worldwide. “There has been a long-standing need for additional effective treatments for treatment resistant depression, a serious and lifethreateningcondition,” Tiffany Farchione,MD, acting director of the FDA’s Division of Psychiatry Products, said in a statement. Marketed as Spravato, the drug is indicated for patients whose depressive symptoms haven’t improved [...]
Lire la suiteEffects of Cannabis Use on Sedation Requirements for Endoscopic Procedures Mark A. Twardowski, Margaret M. Link, Nicole M. Twardowski The Journal of the American Osteopathic Association, 2019 (Published online April 15, 2019). doi:10.7556/jaoa.2019.052 Context : Cannabis (or marijuana) became legal for recreational use in Colorado in 2012, and this legislation change has created both challenges and opportunities in medicine. More patients are using cannabis, and more patients are now willing to admit cannabis use than in the past, which increases the likelihood that they will be forthcoming about use during medical questioning. Cannabis use may have implications during medical care, including procedural sedation. Objective : [...]
Lire la suiteCannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, Gema Moreno-Bueno, Juana M Flores, Isabel García-Real, José Palacios, Santos Mañes, Manuel Guzmán, Cristina Sánchez Molecular Cancer, 2010, 9, 196 http://www.molecular-cancer.com/content/9/1/196 Abstract Background : ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this [...]
Lire la suiteSafety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study Shelef A., Barak Y., Berger U., Paleacu D., Tadger S., Plopsky I., Baruch Y. Journal of Alzheimer's Disease, 2016, 51, 1, 15-19. DOI: 10.3233/JAD-150915 BACKGROUND : Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE : To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS : Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS : Ten patients completed the trial. Significant reduction [...]
Lire la suiteLSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects Peter Gasser, Katharina Kirchner and Torsten Passie Journal of Psychopharmacology, 2014, 1, 12 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114555249 jop.sagepub.com Abstract Objective : A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with lifethreatening diseases. Participants of this study were included in a prospective follow-up. Method : 12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and [...]
Lire la suiteSafety and Efficacy of Lysergic Acid Diethylamide-Assisted-Psychotherapy for Anxiety Associated With Life-threatening Diseases Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, and Rudolf Brenneisen Journal of Nervous and Mental Diseases, 2014 Abstract : A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with lifethreatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 Kg of LSD (n = 8) or 20 Kg of LSD with an open-label crossover to 200 [...]
Lire la suiteLSD-Assisted Psychotherapy for Anxiety Related to Life-Threatening Illness Category: LSD-Assisted Psychotherapy: MAPS-Sponsored Clinical Trials Location: Solothurn, Switzerland MAPS is proud to sponsor the first study of the therapeutic use of LSD in humans in over 40 years. This study, based in Switzerland, investigates the safety and effectiveness of LSD-assisted psychotherapy in subjects with life-threatening illnesses and who are experiencing associated anxiety. The study received final approval from the BAG (the Swiss DEA) on December 5, 2007, final approval from the Ethics Committee (the Swiss IRB equivalent) on October 30, 2007, and clearance from SwissMedic (the Swiss FDA equivalent) on November 8, 2007. The [...]
Lire la suiteLSD-Assisted Psychotherapy https://maps.org/research/psilo-lsd MAPS has completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s. LSD (lysergic acid diethylamide) is a semi-synthetic compound first developed in 1938 by Dr. Albert Hofmann at the Sandoz pharmaceutical company in Basel, Switzerland. After Dr. Hofmann first discovered its effects in 1943, LSD quickly became recognized for its possible therapeutic effects. LSD also played a significant role in the discovery of the serotonin neurotransmitter system. Experimental LSD capsule from our completed Swiss pilot study Our completed Phase 2 pilot study in 12 subjects found positive trends in the reduction of anxiety [...]
Lire la suite